168 related articles for article (PubMed ID: 10657012)
21. Matrix metalloproteinases in carcinoma of unknown primary.
Karavasilis V; Malamou-Mitsi V; Briasoulis E; Tsanou E; Kitsou E; Kalofonos H; Fountzilas G; Fotsis T; Pavlidis N
Cancer; 2005 Nov; 104(10):2282-7. PubMed ID: 16220559
[TBL] [Abstract][Full Text] [Related]
22. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
24. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
25. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
26. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
Wan Y; Wei Q; Pan Y; Liu Y
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):510-3. PubMed ID: 11832095
[TBL] [Abstract][Full Text] [Related]
27. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
[TBL] [Abstract][Full Text] [Related]
28. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
29. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
[TBL] [Abstract][Full Text] [Related]
30. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease.
Rosemar A; Ivarsson ML; Börjesson L; Holmdahl L
Scand J Gastroenterol; 2007 Feb; 42(2):215-20. PubMed ID: 17327941
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
[TBL] [Abstract][Full Text] [Related]
32. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
[TBL] [Abstract][Full Text] [Related]
33. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
34. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the human lens: implications for cortical cataract formation.
Sachdev NH; Di Girolamo N; Nolan TM; McCluskey PJ; Wakefield D; Coroneo MT
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4075-82. PubMed ID: 15505058
[TBL] [Abstract][Full Text] [Related]
36. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue.
Lichtinghagen R; Musholt PB; Stephan C; Lein M; Kristiansen G; Hauptmann S; Rudolph B; Schnorr D; Loening SA; Jung K
Anticancer Res; 2003; 23(3B):2617-24. PubMed ID: 12894549
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer].
Drác P; Klein J; Tichý T; Kolek V; Skarda J
Cas Lek Cesk; 2007; 146(1):45-7. PubMed ID: 17310584
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
39. [Expression of bone morphogenetic proteins, matrix metalloproteinases and inhibitors of matrix metalloproteinases in lung cancers and their prognostic significance].
Bieniasz M; Bartkowiak J; Szemraj J
Postepy Biochem; 2008; 54(1):82-90. PubMed ID: 18610585
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer.
Liu D; Nakano J; Ishikawa S; Yokomise H; Ueno M; Kadota K; Urushihara M; Huang CL
Lung Cancer; 2007 Dec; 58(3):384-91. PubMed ID: 17728005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
